Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C14H21NO.ClH |
| Molecular Weight | 255.784 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.CCCN1CCC[C@H](C1)C2=CC(O)=CC=C2
InChI
InChIKey=NRHUDETYKUBQJT-BTQNPOSSSA-N
InChI=1S/C14H21NO.ClH/c1-2-8-15-9-4-6-13(11-15)12-5-3-7-14(16)10-12;/h3,5,7,10,13,16H,2,4,6,8-9,11H2,1H3;1H/t13-;/m1./s1
(-)-3-(3-hydroxyphenyl)-N-n-propylpiperidine ((-)-3-PPP, also known as preclamol) has a dual action towards to dopamine D2 autoreceptor: it activates it and also acts concomitantly as an antagonist at postsynaptic DA receptors. It was shown, that (-)-3PPP/preclamol was a safe drug for study in the treatment of schizophrenia and may have antipsychotic efficacy. Besides, the motor effects of the drug were evaluated in nine patients with Parkinson's disease using a double-blind, placebo-controlled design. However, the small number of patients manifesting a clinically significant response and the frequently inconsistent effects could indicate that this class of agents may have relatively limited clinical utility.
Approval Year
Sample Use Guides
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
DTXSID401017949
Created by
admin on Sat Dec 16 05:14:22 GMT 2023 , Edited by admin on Sat Dec 16 05:14:22 GMT 2023
|
PRIMARY | |||
|
11957669
Created by
admin on Sat Dec 16 05:14:22 GMT 2023 , Edited by admin on Sat Dec 16 05:14:22 GMT 2023
|
PRIMARY | |||
|
88768-67-6
Created by
admin on Sat Dec 16 05:14:22 GMT 2023 , Edited by admin on Sat Dec 16 05:14:22 GMT 2023
|
PRIMARY | |||
|
Q8W2T87WWW
Created by
admin on Sat Dec 16 05:14:22 GMT 2023 , Edited by admin on Sat Dec 16 05:14:22 GMT 2023
|
PRIMARY |
PARENT (SALT/SOLVATE)
SUBSTANCE RECORD
